DORNASE ALPHA (PULMOZYME) FOR THE COMPLEX TREATMENT OF BRONCHOPULMONARY PROCESS IN CYSTIC FIBROSIS PATIENTS.
- Authors: Sherman V.D.1, Kapranov N.I.1, Kashirskaya N.Y.1, Sherman VD1, Kapranov NI1, Kashirskaya NY.1
-
Affiliations:
- Issue: No 11 (2011)
- Pages: 42-45
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278929
- ID: 278929
Cite item
Full Text
Abstract
The article describes current understanding of the pathogenesis and clinical course of cystic fibrosis (CF). The modern treatment options for cystic fibrosis using Pulmozyme® (dornase alfa), a purified solution of recombinant human deoxyribonuclease 1, produced by the pancreas and other tissues, are discussed. The results of evaluation of safety and efficacy of dornase alfa in 108 children of different age groups with moderate and severe disease observed in the Russian Center of Cystic Fibrosis are presented. It is emphasized that in addition to mucolytic effect, dornase alfa has a number of nonmucolitic effects, such as reduction of neutrophil elastase and interleukin-8 concentrations in the sputum of patients with mucoid Pseudomonas aeruginosa, and inhibition of the formation of mucoid Pseudomonas aeruginosa biofilms determining antibiotic resistance and immune response. It was found that the intranasal administration of Pulmozyme in CF patients with chronic rhinosinusitis
is effective.
is effective.
Keywords
About the authors
Viktoriya Davidovna Sherman
Nikolay Ivanovich Kapranov
Nataliya Yur'evna Kashirskaya
V D Sherman
N I Kapranov
N Yu Kashirskaya
References
- Hodson M, Geddes D. Cystic Fibrosis. Chapman-London. 1995. 439 р.
- Kelly D. Diseases of the liver and biliary system in children. 1998. р. 141-49.
- Milla CE. Long term effects of aerosolized rhDNase on pulmonary disease progression in patients with cystic fibrosis. Thorax 1998;53:1014-17.
- Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human b-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-60.
- Regnis JA, Robinson M, Baileu DL. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am J Respir Crit Care Med 1994;150:66-71.
- Yu H, Nasr SZ, Deretic V. Innate Lung Defenses and Compromised Pseudomonas aeruginosa Clearance in the Malnourished Mouse Model of Respiratory Infections in Cystic Fibrosis. Infect Immun 2000;68(4):2142-47.
- Berger M, Sorensen RU, Tosi MF, et al. Complement receptor exspression on neutrophils at an inflammatory site the pseudomonas-infected lung in cystic fibrosis J Clin Invest 1989;84:1303-13.
- Verhaeghe C, Delbecque K, de Leval L, et al. Early inflammation in the airways of a cystic fibrosis foetus. J Cyst Fibros 2007;6(4):304-08.
- Travis J. Structure, function, and control of neutrophil proteinases. Am J Med 1988;84:37-41.
- Воронкова А.Ю. Клиническая эффективность и безопасность дорназы-альфа ("Пульмозим") в лечении детей, больных муковисцидозом. Автреф. канд. дисс. М., 2004.
- Шелепнева Н.Е, Капранов Н.И., Каширская Н.Ю. и др. Клиническое значение Пульмозима в комплексной терапии детей раннего возраста, больных муковисцидозом // Материалы IX Национального конгресса по муковисцидозу «Муковисцидоз у детей и взрослых-2009». С. 88-9.
- Воронкова А.Ю., Шмарина Г.В., Дубовик Л.Г. и др. Дорназа альфа: клинические и лабораторные эффекты // Пульмонология. 2006. Приложение по муковисцидозу. С. 25-9.
- Волков И.К. Муколитическая терапия при хронических бронхитах у детей // Фарматека. 2006. № 14.
- Merkus PJFM, de Hoog M, Van Gent R, et al. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18:734-47.
- Desai M, Weller PH, Spenser DA Clinical benefit nebulized human recombinant DNase in Kartagener's syndrome. Pediatr Pulmonol 1995;20(5):307-08.
- Cimmino M, Tardone M, Cavaliere M, et al. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Head Neck Surg 2005;131:1097-101.
- Mainz JG, Mentzel HJ, Schneider G, et al. Sinu-nasal inhalation of dornase alfa in CF. Results of a double-blind placebo-controlled pilot trial. J Cystic Fibrosis 2008;7:27.
- Ашерова И.К., Тараканова В.В. Рецидивирующий полисинусит как ведущий клинический признак муковисцидоза: успешное эндоназальное применение дорназы альфа // Фарматека. 2010 . № 14. С. 66-8.
- Sanders NN, Franckx H, Boeck K, et al. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Thorax 2006;61(11):962-68.
- Akbar A, Rees JHM, Nyamugunduru G, et al. Aminoglycoside associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr 1999;88783:785.
- Капранов Н.И., Каширская Н.Ю., Толстова В.Д. Муковисцидоз. Ребенок и лекарство. Справочное пособие для детских врачей (издание второе). Редактор Царегородцев А.Д. Т. 2 Фармакотерапия в педиатрии. М., Изд-во Оверлей, 2008.
Supplementary files
